Literature DB >> 20719582

Development of an LC-MS/MS assay to determine plasma pharmacokinetics of the radioprotectant octadecenyl thiophosphate (OTP) in monkeys.

Hari Kosanam1, Fei Ma, Hui He, Suma Ramagiri, Veeresa Gududuru, Gabor J Tigyi, Koen Van Rompay, Duane D Miller, Charles R Yates.   

Abstract

Octadecenyl thiophosphate (OTP), a synthetic analogue of the lysophospholipid growth factor lysophosphatidic acid (LPA), significantly reduces mortality following a lethal dose of LD(80/30) radiation exposure in a mouse model of whole-body irradiation. To facilitate dose scaling between species, we developed a novel liquid chromatography/tandem mass spectrometry (LC-MS/MS) for the preclinical pharmacokinetic characterization of OTP in monkeys. Sample extraction was carried out using a butanol based liquid-liquid extraction method. A partially deuterated OTP analogue was used as internal standard (IS). OTP and IS were separated by reversed-phase liquid chromatography on a C-8 column using 10mM ammonium acetate and acetonitrile. A triple quadrupole mass spectrometer operating in the negative electrospray ionization mode with multiple reaction monitoring was used to detect OTP and IS transitions of m/z 363.1-->95.0 and 403.1-->95.0. The method was applied to determine pharmacokinetic parameters in monkeys receiving a single oral OTP dose (3mg/kg). OTP is readily absorbed with a relatively long half-life which supports further preclinical testing of OTP as a radioprotectant in monkeys. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719582      PMCID: PMC2965032          DOI: 10.1016/j.jchromb.2010.07.004

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  13 in total

Review 1.  Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS.

Authors:  Raymond Naxing Xu; Leimin Fan; Matthew J Rieser; Tawakol A El-Shourbagy
Journal:  J Pharm Biomed Anal       Date:  2007-02-13       Impact factor: 3.935

2.  High performance liquid chromatography mobile phase composition optimization for the quantitative determination of a carboxylic acid compound in human plasma by negative ion electrospray high performance liquid chromatography tandem mass spectrometry.

Authors:  M Jemal; Z Ouyang; D S Teitz
Journal:  Rapid Commun Mass Spectrom       Date:  1998       Impact factor: 2.419

Review 3.  Application of LC/MS and related techniques to high-throughput drug discovery.

Authors:  Alfonso Espada; Manuel Molina-Martin; Jeffrey Dage; Ming-Shang Kuo
Journal:  Drug Discov Today       Date:  2008-04-21       Impact factor: 7.851

Review 4.  New metabolically stabilized analogues of lysophosphatidic acid: agonists, antagonists and enzyme inhibitors.

Authors:  G D Prestwich; Y Xu; L Qian; J Gajewiak; G Jiang
Journal:  Biochem Soc Trans       Date:  2005-12       Impact factor: 5.407

5.  Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.

Authors:  Gangadhar G Durgam; Tamas Virag; Michelle D Walker; Ryoko Tsukahara; Satoshi Yasuda; Karoly Liliom; Laurens A van Meeteren; Wouter H Moolenaar; Nicole Wilke; Wolfgang Siess; Gabor Tigyi; Duane D Miller
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

6.  Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity.

Authors:  Lian Qian; Yong Xu; Yutaka Hasegawa; Junken Aoki; Gordon B Mills; Glenn D Prestwich
Journal:  J Med Chem       Date:  2003-12-18       Impact factor: 7.446

7.  Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy.

Authors:  G H Anno; S J Baum; H R Withers; R W Young
Journal:  Health Phys       Date:  1989-06       Impact factor: 1.316

8.  The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury.

Authors:  Wenlin Deng; E Shuyu; Ryoko Tsukahara; William J Valentine; Gangadhar Durgam; Veeresa Gududuru; Louisa Balazs; Venkatraman Manickam; Marcello Arsura; Lester VanMiddlesworth; Leonard R Johnson; Abby L Parrill; Duane D Miller; Gabor Tigyi
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

Review 9.  Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001.

Authors:  C Norman Coleman; William F Blakely; John R Fike; Thomas J MacVittie; Noelle F Metting; James B Mitchell; John E Moulder; R Julian Preston; Thomas M Seed; Helen B Stone; Philip J Tofilon; Rosemary S L Wong
Journal:  Radiat Res       Date:  2003-06       Impact factor: 2.841

Review 10.  Lysophospholipid receptors: signaling and biology.

Authors:  Isao Ishii; Nobuyuki Fukushima; Xiaoqin Ye; Jerold Chun
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

View more
  8 in total

1.  Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Authors:  Shannon K Oda; Pamela Strauch; Yuko Fujiwara; Amin Al-Shami; Tamas Oravecz; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

Review 2.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

3.  Lysophosphatidic acid receptor agonists and antagonists (WO2010051053).

Authors:  Abby L Parrill
Journal:  Expert Opin Ther Pat       Date:  2011-01-11       Impact factor: 6.674

4.  Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.

Authors:  Renuka Gupte; Renukadevi Patil; Jianxiong Liu; Yaohong Wang; Sue C Lee; Yuko Fujiwara; James Fells; Alyssa L Bolen; Karin Emmons-Thompson; C Ryan Yates; Anjaih Siddam; Nattapon Panupinthu; Truc-Chi T Pham; Daniel L Baker; Abby L Parrill; Gordon B Mills; Gabor Tigyi; Duane D Miller
Journal:  ChemMedChem       Date:  2011-04-04       Impact factor: 3.466

5.  Mitigation of the hematopoietic and gastrointestinal acute radiation syndrome by octadecenyl thiophosphate, a small molecule mimic of lysophosphatidic acid.

Authors:  Wenlin Deng; Yasuhiro Kimura; Veeresh Gududuru; Wenjie Wu; Andrea Balogh; Erzsebet Szabo; Karin Emmons Thompson; C Ryan Yates; Louisa Balazs; Leonard R Johnson; Duane D Miller; Jur Strobos; W Shannon McCool; Gabor J Tigyi
Journal:  Radiat Res       Date:  2015-03-25       Impact factor: 2.841

6.  Mitigation of radiation injury by selective stimulation of the LPA(2) receptor.

Authors:  Gyöngyi N Kiss; Sue-Chin Lee; James I Fells; Jianxiong Liu; William J Valentine; Yuko Fujiwara; Karin Emmons Thompson; Charles R Yates; Balázs Sümegi; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2013-01

Review 7.  Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.

Authors:  David N Brindley; Fang-Tsyr Lin; Gabor J Tigyi
Journal:  Biochim Biophys Acta       Date:  2012-08-29

8.  LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling.

Authors:  Divij Mathew; Kimberly N Kremer; Pamela Strauch; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.